Tag: Complement system

Hereditary angioedema (HAE) is a rare genetic disorder affecting an estimated 1 in 50,000 people worldwide [1.4.2]. C1 inhibitor drugs are a primary treatment, working by replacing a crucial protein to prevent or treat severe swelling attacks [1.2.3, 1.2.1].

The human body's immune system contains a complex network of proteins known as the complement system, where **C1 esterase inhibitor** plays a crucial role in regulating inflammation. This protein, which is often referred to by several other names in the medical community, is vital for preventing life-threatening swelling attacks in patients with a specific genetic disorder.

Dermatomyositis is a rare autoimmune disease affecting about 10 in every million U.S. residents [1.3.4]. A key question for patients and clinicians is, how does IVIG work in dermatomyositis to combat the characteristic muscle weakness and skin rashes? [1.4.1, 1.4.5]

Approximately 85% of generalized myasthenia gravis cases are driven by an immune system attack, highlighting the role of complement inhibitors like Eculizumab and avacopan. What is the difference between Eculizumab and avacopan, and how do their targeted actions impact treatment for various autoimmune conditions?

According to preclinical studies and initial clinical data, ARGX-117, now known as empasiprubart, can reduce free circulating C2 levels by up to 99%. This powerful effect is key to understanding what is the mechanism of action of argx 117, a novel therapeutic strategy for treating complement-mediated autoimmune diseases.

Crovalimab is a novel anti-C5 monoclonal antibody approved to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by complement-mediated red blood cell destruction. Its mechanism of action involves a unique recycling technology that enhances its efficiency and allows for convenient subcutaneous dosing every four weeks.